THE ROLE OF PATIENT'S SELF-REPORTED HEALTHRELATED QUALITY OF LIFE AS A PREDICTOR OF OVERALL SURVIVAL IN ADVANCED NON-SMALL CELL LUNG CANCER WITH AGE OVER 75

(>grade II) was recorded. After the median follow-up period after CIRT was 77 months (range, 29–130 months), the Kaplan-Meier estimate of overall survival or disease-specific survival after the CIRT showed that the 5-year survival rate was 78.6% or 92.9%, respectively. Conclusion: Our data demonstrated that CIRT was effective and feasible in treating patients with early-stage NSCLC showing GGO dominant shadow.